Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA

Company explored ‘a number of paths to approval’ with agency, but modest progression-free survival benefit in monotherapy treatment of NRAS-mutant melanoma appears to have doomed the new drug application, which was pulled less than two weeks before advisory committee review.